CARA

0.291

0.27% -0.0008

Dopo l'orario di chiusura: .28 -0.011 -3.78%

Cara Therapeutics Inc (CARA)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché CARA Giù? Forum Previsione Frazionamento azionario

Precedente Chiudi:

$0.2918

Aprire:

$0.29

Volume 24 ore:

277.92K

Relative Volume:

0.81

Capitalizzazione di mercato:

$16.09M

Reddito:

$20.97M

Utile/perdita netta:

$-118.51M

Rapporto P/E:

-0.1413

EPS:

-2.06

Flusso di cassa netto:

$-94.45M

1 W Prestazione:

+9.03%

1M Prestazione:

+5.59%

6M Prestazione:

-62.61%

1 anno Prestazione:

-78.44%

Intervallo 1D:

$0.281

$0.3048

Intervallo di 1 settimana:

$0.26

$0.3199

Portata 52W:

$0.24

$1.40

Cara Therapeutics Inc Stock (CARA) Company Profile

Nome

Cara Therapeutics Inc

Settore

Healthcare (1182)

Industria

Biotechnology (671)

Telefono

203-406-3700

Indirizzo

400 ATLANTIC STREET, SUITE 500, STAMFORD, CT

Dipendente

Cinguettio

Prossima data di guadagno

2024-11-11

Ultimi documenti SEC

CARA's Discussions on Twitter

Cara Therapeutics Inc Stock (CARA) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2023-03-08	Downgrade	BofA Securities	Neutral → Underperform
2022-03-08	Aggiornamento	JP Morgan	Neutral → Overweight
2021-11-01	Ripresa	Canaccord Genuity	Buy
2021-08-03	Iniziato	JP Morgan	Neutral
2020-04-21	Reiterato	H.C. Wainwright	Buy
2019-08-12	Reiterato	H.C. Wainwright	Buy
2019-05-29	Reiterato	Laidlaw	Buy
2019-02-06	Ripresa	Jefferies	Buy
2019-01-15	Iniziato	BofA/Merrill	Neutral
2018-09-21	Iniziato	Cantor Fitzgerald	Overweight
2018-09-13	Iniziato	Jefferies	Buy
2018-08-08	Reiterato	Stifel	Buy
2018-06-28	Reiterato	H.C. Wainwright	Buy
2018-03-12	Ripresa	H.C. Wainwright	Buy
2018-02-12	Aggiornamento	Janney	Neutral → Buy
2018-01-19	Iniziato	Seaport Global Securities	Buy
2017-06-30	Downgrade	Janney	Buy → Neutral
2017-06-30	Reiterato	Laidlaw	Buy
2017-06-30	Reiterato	Stifel	Buy
2017-03-28	Reiterato	H.C. Wainwright	Buy
2017-03-28	Reiterato	Laidlaw	Buy
2017-03-10	Reiterato	Laidlaw	Buy
2016-10-13	Iniziato	H.C. Wainwright	Buy
2016-08-08	Reiterato	Needham	Buy

Mostra tutto

Cara Therapeutics Inc Borsa (CARA) Ultime notizie

01:41 AM

Cara Operations (TSE:CARA) Stock Price Down 2.4% – Here’s Why - Defense World

01:41 AM

Nov 01, 2024

Cara Therapeutics, Inc.'s (NASDAQ:CARA) Share Price Is Matching Sentiment Around Its Revenues - Simply Wall St

Nov 01, 2024

Oct 31, 2024

Rigel Announces Conference Call and Webcast to Report Third Quarter 2024 Financial Results and Business Update - Quantisnow

Oct 31, 2024

Riskified Ltd. (NYSE:RSKD) Given Consensus Recommendation of “Hold” by Analysts - Defense World

Oct 16, 2024

Oct 13, 2024

Heritage Global Inc. (NASDAQ:HGBL) Shares Acquired by Dimensional Fund Advisors LP - Defense World

Oct 13, 2024

Dimensional Fund Advisors LP Purchases 55,636 Shares of VirTra, Inc. (NASDAQ:VTSI) - Defense World

Oct 13, 2024

Renaissance Technologies LLC Reduces Position in Cara Therapeutics, Inc. (NASDAQ:CARA) - Defense World

Oct 13, 2024

Oct 10, 2024

Opioid Use Disorder (OUD) Market Report 2024: Growth, Trends, Competitive Outlook to 2033 - WhaTech

Oct 10, 2024

Oct 09, 2024

Europe Pruritus Therapeutics Market Size & Outlook, 2030 - Grand View Research

Oct 09, 2024

Oct 07, 2024

Financial Health Report: Cara Therapeutics Inc (CARA)’s Ratios Tell a Tale - The Dwinnex

Oct 07, 2024

What technical indicators reveal about CARA stock - US Post News

Oct 07, 2024

Oct 04, 2024

Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Quantisnow

Oct 04, 2024

Medical Marijuana Market Report 2024Growth, Forecast In The Latest Research - WhaTech

Oct 04, 2024

Cara Therapeutics (NASDAQ:CARA) Receives New Coverage from Analysts at StockNews.com - Defense World

Oct 04, 2024

Sep 30, 2024

Market Recap: Cara Therapeutics Inc (CARA)’s Positive Momentum, Closing at 0.31 - The Dwinnex

Sep 30, 2024

Sep 29, 2024

Cara Therapeutics, Inc. (NASDAQ:CARA) Sees Large Increase in Short Interest - Defense World

Sep 29, 2024

Sep 26, 2024

Stock Analysts’ New Coverage for September 26th (AINC, AIRI, APTO, BLK, CARA, CBOE, CLLS, CME, CMLS, CTLT) - Defense World

Sep 26, 2024

Sep 25, 2024

G-Protein Coupled Receptors Market Growth Analysis, Trends, Share, Market Size And Forecast To 2033 - WhaTech

Sep 25, 2024

Sep 23, 2024

A closer look at Cara Therapeutics Inc (CARA) is warranted - US Post News

Sep 23, 2024

Sep 21, 2024

WesBanco, Inc. (NASDAQ:WSBC) Receives Consensus Rating of “Hold” from Analysts - Defense World

Sep 21, 2024

Sep 19, 2024

Pruritus Clinical Trials 2024: FDA Approvals, Medication, - openPR

Sep 19, 2024

Sep 18, 2024

Ra capital executives buy Bicara Therapeutics shares for $32.99m By Investing.com - Investing.com Canada

Sep 18, 2024

Aclaris Therapeutics neutral rating reiterated on phase 2a trial - Investing.com

Sep 18, 2024

Federated Hermes Inc. Acquires Shares of 670,468 Sage Therapeutics, Inc. (NASDAQ:SAGE) - Defense World

Sep 18, 2024

Carmat launches capital increase, stock plummets - Marketscreener.com

Sep 18, 2024

Sep 17, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Sage Therapeutics, Inc. of Class Action Lawsuit and Upcoming DeadlinesSAGE - PR Newswire

Sep 17, 2024

Most Promising New Drugs for Hidradenitis Suppurativa, with Raj Chovatiya, MD, PhD - MD Magazine

Sep 17, 2024

Sep 16, 2024

The time has not yet come to remove your chips from the table: Cara Therapeutics Inc (CARA) - SETE News

Sep 16, 2024